Corrigendum to "The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions" [Thromb. Res. 212 (2022) 72-80]

M F A Karel; B M E Tullemans; G D'Italia; T P Lemmens; T A M Claushuis; M J E Kuijpers; J M E M Cosemans

doi:10.1016/j.thromres.2022.03.012

Corrigendum to "The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions" [Thromb. Res. 212 (2022) 72-80]

M F A Karel, B M E Tullemans, G D'Italia, T P Lemmens, T A M Claushuis, M J E Kuijpers, J M E M Cosemans^*

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Original language	English
Pages (from-to)	113-113
Number of pages	1
Journal	Thrombosis Research
Volume	213
Early online date	22 Mar 2022
DOIs	https://doi.org/10.1016/j.thromres.2022.03.012
Publication status	Published - Apr 2022

Access to Document

10.1016/j.thromres.2022.03.012

1 Article

The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions
Karel, M. F. A., Tullemans, B. M. E., D'Italia, G., Lemmens, T. P., Claushuis, T. A. M., Kuijpers, M. J. E. & Cosemans, J. M. E. M., Apr 2022, In: Thrombosis Research. 212, p. 72-80 9 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access

Cite this

Karel, M. F. A., Tullemans, B. M. E., D'Italia, G., Lemmens, T. P., Claushuis, T. A. M., Kuijpers, M. J. E., & Cosemans, J. M. E. M. (2022). Corrigendum to "The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions" [Thromb. Res. 212 (2022) 72-80]. Thrombosis Research, 213, 113-113. https://doi.org/10.1016/j.thromres.2022.03.012

@article{dfdbe92bf047438aac0ecba9a50f66c8,

title = "Corrigendum to {"}The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions{"} [Thromb. Res. 212 (2022) 72-80]",

author = "Karel, {M F A} and Tullemans, {B M E} and G D'Italia and Lemmens, {T P} and Claushuis, {T A M} and Kuijpers, {M J E} and Cosemans, {J M E M}",

year = "2022",

month = apr,

doi = "10.1016/j.thromres.2022.03.012",

language = "English",

volume = "213",

pages = "113--113",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier Science",

}

TY - JOUR

T1 - Corrigendum to "The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions" [Thromb. Res. 212 (2022) 72-80]

AU - Karel, M F A

AU - Tullemans, B M E

AU - D'Italia, G

AU - Lemmens, T P

AU - Claushuis, T A M

AU - Kuijpers, M J E

AU - Cosemans, J M E M

PY - 2022/4

Y1 - 2022/4

U2 - 10.1016/j.thromres.2022.03.012

DO - 10.1016/j.thromres.2022.03.012

M3 - Erratum / corrigendum / retractions

C2 - 35334440

SN - 0049-3848

VL - 213

SP - 113

EP - 113

JO - Thrombosis Research

JF - Thrombosis Research

ER -